Pfizer - International Biopharmaceutical Industry

news

Pfizer lures research chief from Roche, prompting high-level reshuffle

Dive Brief: Pfizer is hiring William Pao, currently Roche's head of pharmaceutical research and early development, to serve as its chief development officer and ex...

6 February 2022 news Comirnaty | COVID-19

Continue Reading →

news

With new trial, Pfizer and BioNTech will test whether an omicron vaccine is needed

Dive Brief: Pfizer and BioNTech have begun enrolling patients in a study testing a new version of their COVID-19 vaccine specifically tailored to the omicron varia...

27 January 2022 news BioNTech | COVID-19

Continue Reading →

news

Moderna follows Pfizer in beginning trial of omicron vaccine

Dive Brief: Moderna on Wednesday said it has begun a trial testing a new version of its COVID-19 vaccine that's tailored to the omicron variant, one day after Pfiz...

27 January 2022 news booster | COVID-19

Continue Reading →

news

FDA approves AbbVie, Pfizer drugs for eczema, creating competition for Sanofi

Dive Brief: The top-selling product for French pharmaceutical giant Sanofi now has two more competitors in the U.S. market, as the Food and Drug Administration on ...

20 January 2022 news ABBVIE | eczema

Continue Reading →

news

Pfizer’s big bet on mRNA, Biogen ‘proven wrong’ on Aduhelm price and the next cell therapies

Biotechnology stocks ended the first day of the J.P. Morgan Healthcare Conference in the green, but only barely. By Monday afternoon, a closely followed index of the ...

14 January 2022 news Alzheimer | cell

Continue Reading →

news

COVID-19 pills from Pfizer, Merck authorized by FDA in major pandemic milestone

Paxlovid and molnupiravir are the first oral treatments for COVID-19, potentially valuable new tools as the fast-spreading omicron variant fuels a sharp surge in case...

7 January 2022 news COVID-19 pills | FDA

Continue Reading →

news

In final analysis, Pfizer’s COVID-19 pill remains highly effective

Final study results show Pfizer's experimental COVID-19 pill remained as effective as indicated by preliminary data last month, a major relief after promising data fo...

15 December 2021 news COVID-19 pill | data

Continue Reading →

news

Lilly deepens research ties in China with biotech deal

Lilly's deal with Regor is another example of large pharmaceutical companies in the U.S. and Europe showing interest in Chinese biotechs for their research, rather th...

13 December 2021 news Amgen | Chinese biotech

Continue Reading →

news

Arena, completing its turnaround, sells to Pfizer for nearly $7 billion

Pfizer has agreed to acquire Arena Pharmaceuticals for about $6.7 billion in a deal that validates the San Diego biotech’s plan to reshape itself around a portfolio o...

13 December 2021 news acquisition | Arena Pharmaceuticals

Continue Reading →

news

AbbVie’s blockbuster weighed down by safety concerns for a similar Pfizer drug

For years, AbbVie's business has relied on Humira. One of the world's top-selling medicines, Humira brought in close to $20 billion for AbbVie in each of the last thr...

10 December 2021 news ABBVIE | Humira

Continue Reading →

Current Edition

Upcoming Events

Advertisement

Pfizer lures research chief from Roche, prompting high-level reshuffle

With new trial, Pfizer and BioNTech will test whether an omicron vaccine is needed

Moderna follows Pfizer in beginning trial of omicron vaccine

FDA approves AbbVie, Pfizer drugs for eczema, creating competition for Sanofi

Pfizer’s big bet on mRNA, Biogen ‘proven wrong’ on Aduhelm price and the next cell therapies

COVID-19 pills from Pfizer, Merck authorized by FDA in major pandemic milestone

In final analysis, Pfizer’s COVID-19 pill remains highly effective

Lilly deepens research ties in China with biotech deal

Arena, completing its turnaround, sells to Pfizer for nearly $7 billion

AbbVie’s blockbuster weighed down by safety concerns for a similar Pfizer drug

International Biopharmaceutical Industry